IMMU Immunicum AB

Mendus deltar i flera konferenser i juni 2023

Mendus deltar i flera konferenser i juni 2023

Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier som tar sig an tumöråterfall, tillkännager idag sitt deltagande i följande kommande investerar- och industrikonferenser:



Redeye Growth Day

Online, 1 juni 2023

Mendus VD Erik Manting kommer att delta i en frågestund den 1 juni. Ytterligare information inklusive nedladdningsbar företagspresentation finns tillgänglig via:



BIO International Convention

Boston, USA, 5-8 juni 2023

Erik Manting. VD på Mendus, kommer att medverka pa konferensen.



EHA2023 Hybrid Congress

Frankfurt, Tyskland och online, 8-11 juni, 2023

Mendus kommer att presentera uppdateringar avseende immunmonitoreringssdata från

ADVANCE II-studien och framsteg avseende företagets program for NK-cellterapi.



FÖR MER INFORMATION VÄNLIGEN KONTAKTA:

Erik Manting

VD

E-post:



INVESTOR RELATIONS

Corey Davis

LifeSci Advisors, LLC

Telefon: 7

E-post:



MEDIAKONTAKTER

Mario Brkulj

Valency Communications

Telefon: 51

E-post:



OM MENDUS AB (PUBL)

Mendus förändrar behandlingen av cancer genom att ta itu med tumöråterfall och förbättra överlevnadsresultaten för cancerpatienter, samtidigt som livskvaliteten bevaras. Vi utnyttjar vår oöverträffade expertis inom allogen dendritcellsbiologi för att utveckla en avancerad klinisk pipeline av nya, lagringsbara, cellbaserade immunterapier som kombinerar klinisk effekt med en godartad säkerhetsprofil. Mendus är baserat i Sverige och Nederländerna och handlas på Nasdaq Stockholm under tickern IMMU.ST.

Bilaga



EN
25/05/2023

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Regulatory green light for CADENCE trial

The Human Research Ethics Committee (HREC) has provided the green light to commence enrolment for Mendus’s AMLM22-CADENCE trial from April 2024. This Phase II trial in collaboration with the Australasian Leukaemia and Lymphoma Group, a clinical trial research group focused on haematological cancers, will evaluate lead cancer vaccine vididencel, in combination with standard of care oral azacitidine (Onureg) as a maintenance treatment for acute myeloid leukaemia (AML). A pivotal global registratio...

03/28/24 March 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch